BIOCON:NSE
Biocon
348,25 ₹
arrow_downward
-0,50%(-1,75) 1d
9 d’oct., 11:15:57 GMT+5:30 · INR
search
Tots els símbols
| Símbol | Preu | Canvi | Percentatge de canvi |
|---|
insights_autoS'estan generant les estadístiques principals per a BIOCON...
Obre
349,55 ₹
Alt
351,00 ₹
Baix
343,95 ₹
Capitalització borsària
567,24 kM
Volum mitjà
3,09 M
Volum
495,68 k
Dividend
0,14 %
Dividend trimestral
0,12 ₹
Data de l'exdividend
3 de jul. 2026
Ràtio preu-benefici
103,10
Alt 52 setmanes
447,15 ₹
Baix 52 setmanes
337,70 ₹
BPA
3,38 ₹
Accions en circulació
600,00 M
Nombre d'empleats
16 k
Obre
349,55 ₹
Alt
351,00 ₹
Baix
343,95 ₹
Capitalització borsària
567,24 kM
Volum mitjà
3,09 M
Volum
495,68 k
Dividend
0,14 %
Dividend trimestral
0,12 ₹
Data de l'exdividend
3 de jul. 2026
Ràtio preu-benefici
103,10
Alt 52 setmanes
447,15 ₹
Baix 52 setmanes
337,70 ₹
BPA
3,38 ₹
Accions en circulació
600,00 M
Nombre d'empleats
16 k
Notícies
De fonts web i partners de notícies
Yahoo Finance UK
·
fa 46 minuts
Quantisimo Corp., the Pure-Play Sovereign Quantum Vertical Platform “Root to Qubit” Formed by WISeQey and SEALSQ, Signs Definitive Business Combination Agreement with GigCapital8 Corp. to Become a Nasdaq-Listed Public Company
The Lufkin Daily News
·
fa 1 hora
FILE PHOTO: Traders react to the Fed rate announcement on the floor of the NYSE in New York
dailyrecordnews.com
·
fa 53 minuts
Asian shares are mixed and crude prices fall after an unsettled day on Wall St
Perfil
Biocon Limited is an Indian biopharmaceutical company based in Bengaluru, with U.S. headquarters in Bridgewater, New Jersey. Founded by Kiran Mazumdar-Shaw in 1978 as a partner to the Irish brewing enzyme manufacturer Biocon Biochemicals Ltd., the company manufactures generic active pharmaceutical ingredients that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics, and branded drugs such as biosimilar insulins and antibodies for the Indian domestic market. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets.
Biocon's formulations for the Indian market include metabolics, oncology, immunotherapy, and nephrology products. Some of Biocon's key brands in India include INSUGEN, BASALOG, BIOMAb EGFR, BLISTO, CANMAb, Evertor, TACROGRAF, ALZUMAb and KRABEVA.
Syngene International Limited is a publicly listed subsidiary of Biocon, operating in the contract research and development organization. Wikipedia
Sobre Biocon
Conseller delegatShreehas P Tambe
Empleats16,4 k
Fundació29 de nov. 1978
Seu principalBangalore, Estat de Karnataka, Índia
Sector-
Lloc webbiocon.com